Drug updated on 11/13/2023

Dosage FormTablet (oral; 10 mg, 50 mg, 100 mg)
Drug ClassBCL-2 inhibitors
Ongoing and Completed


  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Indicated in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Venclexta (venetoclax) Prescribing Information.2022AbbVie Inc., North Chicago, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.2023Annals of Medicine
The Non-Hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-Analysis. 2023Recent patents on Anticancer Drug Discovery
Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies. 2023Cancers
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. 2023Leukemia research
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis. 2023Hematology
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review. 2023Future Oncology
The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. 2023Hematology
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.2022Leukemia & Lymphoma
Clinical and pharmacoeconomic combined report: venetoclax (Venclexta) for acute myeloid leukemia. 2021CADTH
Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.2021Clinical and Experimental Medicine
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia.2020NICE
Final clinical guidance report: venetoclax (Venclexta) obinutuzumab chronic lymphocytic leukemia. 2020CADTH
The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.2020Hematology
Novel targeted therapies for chronic lymphocytic leukemia in elderly patients: a systematic review.2020Clinical Lymphoma, Myeloma and Leukemia
Efficacy and safety of bcl-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials.2019Frontiers in Pharmacology
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. 2019NICE
Final clinical guidance report: venetoclax (Venclexta) rituximab for chronic lymphocytic leukemia.2019CADTH
Final clinical guidance report: venetoclax (Venclexta) for chronic lymphocytic leukemia.2018CADTH

Clinical Practice Guidelines